Company / Cash & Equivalents
Kura Oncology, Inc. Cash & Equivalents History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$149.1M
FY2025
5-year range
$37.3M / $224.5M
FY2021-FY2025
Trend
-33.6%
vs FY2024
Sector context
#115 of 207
Health Care
What the data says
At $149M, Kura Oncology, Inc.'s cash & equivalents ranks #115 of 207 in the Health Care sector. Cash & Equivalents has fluctuated over the past 10 years, ranging from $10M in FY2016 to $325M in FY2020.
Based on SEC 10-K filings.
$149M in FY2025 with a 5-year CAGR of -14.5%.
Improved from $37M to $149M over the past 2 years.
Health Care sector context is included.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- +42.2%
- 5-Year CAGR
- -14.5%
- 10-Year CAGR
- -
Sector benchmark
#115 of 207 in Health CareTop 56% of 207This company $149.1M Sector average $669.5M
▼
-77.7% below sector average
Key checks
Key Insights
- 5-year CAGR of -14.5%, indicating a declining trend.
- In FY2025, cash & equivalents decreased 33.6% year-over-year.
- Ranks #115 out of 207 companies in the Health Care sector.
- Peak cash & equivalents was recorded in FY2020.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -1.83 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $149.1M | -33.6% |
| FY2024 | $224.5M | +501.5% |
| FY2023 | $37.3M | -28.0% |
| FY2022 | $51.8M | -42.9% |
| FY2021 | $90.7M | -72.1% |
| FY2020 | $325.5M | +1145.4% |
| FY2019 | $26.1M | +62.1% |
| FY2018 | $16.1M | +41.0% |
| FY2017 | $11.4M | +17.6% |
| FY2016 | $9.7M | -37.0% |
As of FY2025 · SEC 10-K · Updated Mar 28, 2026